AVITA Medical R&D per Employee
The R&D Spending per Employee of AVITA Medical (RCEL) as of Oct 13, 2026 is 90,088.50 USD. In the previous year, R&D Spending per Employee was 92,128.32 USD — a change of -2.21% (lower).
Get this data via API
Financial Data API
R&D per Employee
90,088.50USD
YoY
-2.21%
Last updated:
R&D Spending per Employee of AVITA Medical is 2024 90,088.50 USD. R&D Spending per Employee of AVITA Medical was 2023 92,128.32 USD. It decreases by -2.21% lower compared to the previous year.
The AVITA Medical R&D per Employee history
3 Years
10 Years
25 Years
Max
R&D per Employee
Date
R&D per Employee
Jan 1, 2019
37,433.63 USD
Jan 1, 2020
65,575.22 USD
Jan 1, 2021
33,566.37 USD
Jan 1, 2022
61,327.43 USD
Jan 1, 2023
92,128.32 USD
Jan 1, 2024
90,088.50 USD
| YEAR | R&D per Employee | YoY |
|---|---|---|
| 90,088.50USD | -2.21% | |
| 92,128.32USD | +50.22% | |
| 61,327.43USD | +82.70% | |
| 33,566.37USD | -48.81% | |
| 65,575.22USD | +75.18% | |
| 37,433.63USD | — |
Access this data via the Eulerpool API
AVITA Medical Stock analysis
What does AVITA Medical do? AVITA Medical Inc is a company in the field of regenerative medicine that focuses on the development and marketing of innovative therapy products for the treatment of burns, chronic wounds, and skin defects. The company was founded in 1998 and is headquartered in Valencia, California. AVITA Medical Inc began with research in the field of regenerative medicine at the University of Western Australia, where the company developed its patented technology known as ReNovaCell. This technology allows for the extraction and cultivation of cells from a small area of skin to create a solution that contains the patient's own skin tissue on a large scale. AVITA Medical Inc's business model is based on the development and marketing of regenerative therapy products based on ReNovaCell technology. The company focuses on commercializing products that enable fast, safe, and effective treatment of burns, chronic wounds, and skin defects. AVITA Medical Inc operates in two main segments: regenerative medicine and aesthetic medicine. In regenerative medicine, the company offers a wide range of products based on ReNovaCell technology, including ReCell, a unique autologous cell therapy for rapid burn treatment, Kelo-Cote, a silicone gel formulation for scar treatment, and therapy-complementary wound treatments. In aesthetic medicine, the company distributes a variety of products under the brand RestoreSkin, which focuses on improving skin health and aesthetic appearance, including pore refinement, pigment reduction, and wrinkle reduction. AVITA Medical Inc has established itself as a leading provider of regenerative therapy products. The company has a strong presence both in the US and internationally and is actively advocating for the advancement of regenerative medicine. By developing innovative products that enable fast and effective treatment of skin defects, AVITA Medical Inc will continue to be a key player in regenerative medicine in the future. AVITA Medical is one of the most popular companies on Eulerpool.
Frequently Asked Questions about AVITA Medical stock
R&D Spending per Employee of AVITA Medical is 90,088.50 USD in 2024.
R&D Spending per Employee of AVITA Medical changed from 92,128.32 USD to 90,088.50 USD, representing a -2.21% change. The value is lower than the previous year.
On Eulerpool you can find the complete historical development of R&D Spending per Employee AVITA Medical since 2006 – with annual values, charts, and detailed analysis.
R&D per employee shows the research and development investment allocated per employee. Higher values indicate innovation-focused companies.
R&D Spending per Employee's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track R&D Spending per Employee's AVITA Medical historically and in real time.
Access this data via the Eulerpool API
Workforce — AVITA Medical
All Key Metrics — AVITA Medical
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth